Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

By C. Feig, James O. Jones, Matthew Kraman, R. Wells, A. Deonarine, Derek S. Chan, Claire M. Connell, Edward W. Roberts, Qi Zhao, O. Caballero and 5 more. Proceedings of the National Academy of Sciences of the United States of America, 2013

1,849 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Oncology

View Paper: https://www.semanticscholar.org/paper/0320da3323c2a9b7ea29aea4c3e271a7d75ba513

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. W. Zou
2. Lieping Chen

In Oncology

1. Lieping Chen
2. W. Zou
3. J. Wolchok
4. Thea D. Tlsty
5. Giulia Biffi
6. D. Tuveson
7. D. Öhlund
8. Philippe Gascard

Citations in the corpus

• Fibroblast heterogeneity in the cancer wound (2014, background): “Depletion of FAPpositive cells restored immunological detection and destruction of the tumor, indicating that FAP-positive cells are immune-suppressive cells in the tumor microenvironment (Kraman et al., 2010; Feig et al., 2013).”
• New horizons in tumor microenvironment biology: challenges and opportunities (2015, background): “Both CAFs and CSCs are implicated in the TME-mediated signaling to remodel cancer cells; for instance, CAFs express high levels of extracellular factors including chemokine CXC motif ligand (CXCL)12, chemokine CC motif ligand (CCL)2, CCL8, and insulinlike growth factor binding protein 7, thereby for”
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Targeting tumor stromal fibroblasts (172), CXCL12 and CXCR4 blockade (172), and VEGF-targeted therapy (173) have been tested as combinatorial partners for immunotherapy in the literature.”